Adempas Film Coated Tablets
- Name:
Adempas Film Coated Tablets
- Company:
MSD Ireland (Human Health) Limited
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 17/04/19
(Click to Download)Click on this link to Download PDF directly
MSD Ireland (Human Health) Limited
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 17 April 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 6 - date of revision
Updated on 17 April 2019 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Information on concomitant use with strong multi pathway CYP / P‑glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitors was added to sections 4.2, 4.4, 4.5
Updated on 13 February 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - use in children and adolescents
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 2 - excipient warnings
- Change to section 4 - possible side effects
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
- Removal of Black Inverted Triangle
Updated on 13 February 2019 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
- Improved presentation of SPC
- Removal of Black Inverted Triangle
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Change to section 4.4 (sodium excipient warning); Change to section 4.5 (reference to the recommendation on dose titration)
Updated on 13 March 2018 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 13 March 2018 SPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Change to section 10 (change from January 2018 to March 2018)
Updated on 12 March 2018 PIL
Reasons for updating
- New PIL for new product
Updated on 12 March 2018 PIL
Reasons for updating
- Change to section 6 - date of revision
Updated on 6 March 2018 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 5 March 2018 PIL
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 3 - how to take/use
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 14 November 2017 SPC
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Change to section 5.1 (Update to reflect on results from RISE-IIP, and CHEST-2, PATENT-2 LTE)
Updated on 16 May 2017 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Change to section 7 (MA transfer from Bayer Pharma AG to Bayer AG)
Updated on 15 May 2017 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 20 March 2017 PIL
Reasons for updating
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 3 March 2017 SPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 6.1 - List of excipients
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
- Change from individual to joint SPC
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Change to section 1, 2, 3, 6, 8 (consolidation of different strengths into one SPC) Change to section 4.4, 4.5 (Pregnancy/contraception)
Updated on 25 July 2016 PIL
Reasons for updating
- Addition of information on reporting a side effect.
Updated on 22 July 2016 SPC
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 5.1 - Pharmacodynamic properties
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 21 July 2016 PIL
Reasons for updating
- Change of contraindications
Updated on 6 January 2016 PIL
Reasons for updating
- Change in co-marketing arrangement
Updated on 9 September 2015 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to side-effects
- Change to dosage and administration
- Change to MA holder contact details
Updated on 8 September 2015 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.2: the following text has been added to this section:
Crushed tablets
For patients who are unable to swallow whole tablets, Adempas tablets may be crushed and mixed
with water or soft foods such as applesauce immediately prior to use and administered orally (see
section 5.2).
Section 4.3 has been updated as follows:
- Co-administration with nitrates or nitric oxide donors (such as amyl nitrite) in any form including recreational drugs called ‘poppers’ (see section 4.5).
Section 4.5 has been updated as follows:
Pharmacodynamic interactions
Nitrates
In a clinical study the highest dose of Adempas (2.5 mg tablets three times daily) potentiated the blood pressure lowering effect of sublingual nitroglycerin (0.4 mg) taken 4 and 8 hours after intake. Therefore co-administration of Adempas with nitrates or nitric oxide donors (such as amyl nitrite) in
any form, including recreational drugs called ‘poppers’, is contraindicated (see section 4.3).
Section 5.1: the following changes were made to the subsections:
|
Patient population with CTEPH post-PEA |
Riociguat (n=52) |
Placebo (n=20) |
|
Baseline (m) [SD] |
360 [78] |
374 [72] |
|
Mean change from baseline (m) [SD] |
27 [68] |
1.8 [73] |
|
Placebo‑ adjusted 95% CI |
27 -10 to 63 |
|
LS=least squares
Adverse Events leading to discontinuation occurred at a similar frequency in both treatment groups
(riociguat individual dose titration (IDT) 1.0-2.5 mg, 2.9%; placebo, 2.3%).
Section 5.2: the following text was added:
Bioavailability (AUC and Cmax) is comparable for Adempas administered orally as a crushed tablet
suspended in applesauce or in water compared to a whole tablet (see section 4.2).
Updated on 27 November 2014 SPC
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The date of revision has been updated
Updated on 27 November 2014 PIL
Reasons for updating
- Change to date of revision
- Introduction of new pack/pack size
- Addition of information on reporting a side effect.
Updated on 1 August 2014 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 1 August 2014 PIL
Reasons for updating
- New PIL for new product